Seller record · Research vendor

Umbrella Labs

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S1, prescriber requirement: No clinician evaluation is claimed anywhere on the site, and the stated condition of sale is laboratory research use only. 2 more criteria also fail; see the table below.

At a glance

Umbrella LabsResearch vendor

5/8criteria passed

Price: Printed on its own pages before sign-up
Sells: research peptides including semaglutide, retatrutide, cagrilintide and survodutide, and 5 more
FDA letters: None on file

Visit Umbrella Labs See all eight dispositions

Research vendor. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A research compound seller offering peptides, SARMs, nootropics and research chemicals, among them semaglutide and four other GLP-1 analogues labeled for laboratory use. It publishes a certificate library of public files that open with no login.

Operating entity Umbrella Labs, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	FAIL	Umbrella Labs' terms of service page
S2	Prescription gating	FAIL	Umbrella Labs' checkout
S3	Pharmacy identification	FAIL	Umbrella Labs' terms of service page
S4	Compounding disclosure	PASS	Umbrella Labs' the nucleus page
S5	Analytical documentation	PASS	Umbrella Labs' semaglutide certificate of analysis
S6	Business address	PASS	Umbrella Labs' contact page
S7	Price disclosure	PASS	Umbrella Labs' semaglutide peptide powder tablets product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1FAILNo clinician evaluation is claimed anywhere on the site, and the stated condition of sale is laboratory research use only.Source: Umbrella Labs' terms of service page.

S2FAILA guest checkout collects billing details with no eligibility question, starting from the semaglutide tablet page at 159.99 dollars.Source: Umbrella Labs' checkout.

S3FAILNo pharmacy is named anywhere on the site, and a site-wide notice states that the seller is not a compounding pharmacy under section 503A.Source: Umbrella Labs' terms of service page.

S4PASSThe seller offers no compounded drug, states in a site-wide notice that it is not a compounding pharmacy, and prints that its statements are not evaluated by the Food and Drug Administration.Source: Umbrella Labs' the nucleus page.

S5PASSA public certificate from Vanguard Laboratory of Olympia reports chromatographic purity above 99.80 percent on semaglutide lot ULP-48813 by HPLC, reachable with no login.Source: Umbrella Labs' semaglutide certificate of analysis.

S6PASSThe contact page and the privacy policy print a street address with a suite number at 3280 East Hemisphere Loop in Tucson, Arizona.Source: Umbrella Labs' contact page.

S7PASSThe semaglutide tablet page prints 159.99 dollars for thirty tablets at 7 mg each with no account required, and the cart carries the same figure.Source: Umbrella Labs' semaglutide peptide powder tablets product page.

S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: research peptides including semaglutide, retatrutide, cagrilintide and survodutide, peptide tablets and capsules, SARMs, nootropics, research chemicals, laboratory supplies.

Other sellers of the same products

Who sells semaglutide Who sells cagrilintide Who sells retatrutide

Visit Umbrella Labs

535 sellers pass S1, prescriber requirement

See all 535 on the S1 criterion page — 527 more than shown here.

This seller fails criteria a medical service must meet. The records above belong to sellers that pass S1; some are partner links, disclosed on their records.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.